

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7756782/jose-l-ferreiro-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|-------------------|-------------------------|----------------|-----------------|
| 82 papers | 2,262 citations | 25 h-index | 45 g-index |
| 92 ext. papers | 2,587 ext. citations | 3.9 avg, IF | 4.92 L-index |

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 82 | Diabetes and antiplatelet therapy in acute coronary syndrome. <i>Circulation</i> , 2011 , 123, 798-813 | 16.7 | 229 |
| 81 | Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1139-46 | 15.1 | 169 |
| 80 | Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 180-7 | 6 | 151 |
| 79 | Platelet abnormalities in diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2010 , 7, 251-9 | 3.3 | 138 |
| 78 | Impaired responsiveness to the platelet P2Y ₁₂ receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1005-14 | 15.1 | 121 |
| 77 | Clopidogrel response variability: current status and future directions. <i>Thrombosis and Haemostasis</i> , 2009 , 102, 7-14 | 7 | 91 |
| 76 | Platelet function testing and risk of bleeding complications. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 1128-35 | 7 | 79 |
| 75 | Cangrelor: a review on its mechanism of action and clinical development. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 1195-201 | 2.5 | 71 |
| 74 | Noninvasive Follow-Up of Patients With Spontaneous Coronary Artery Dissection With CT Angiography. <i>JACC: Cardiovascular Imaging</i> , 2016 , 9, 896-897 | 8.4 | 61 |
| 73 | Inhibición del receptor plaquetario P2Y ₁₂ de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras. <i>Revista Española De Cardiología</i> , 2010 , 63, 60-76 | 1.5 | 58 |
| 72 | A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 42-50 | 5 | 55 |
| 71 | New directions in antiplatelet therapy. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 433-45 | 6 | 52 |
| 70 | Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. <i>Circulation: Cardiovascular Interventions</i> , 2010 , 3, 436-41 | 6 | 47 |
| 69 | Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 30-9 | 15.1 | 44 |
| 68 | Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 769-77 | 15.1 | 38 |
| 67 | Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. <i>JACC: Cardiovascular Interventions</i> , 2012 , 5, 293-300 | 5 | 38 |
| 66 | Impact on delay times and characteristics of patients undergoing primary percutaneous coronary intervention in the southern metropolitan area of Barcelona after implementation of the infarction code program. <i>Revista Española De Cardiología</i> , 2012 , 65, 911-8 | 1.5 | 35 |

| | | | |
|----|---|------|----|
| 65 | Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents. <i>American Journal of Cardiovascular Drugs</i> , 2013 , 13, 233-50 | 4 | 35 |
| 64 | Functional profile of the platelet P2Y ₁ receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2011 , 105, 730-2 | 7 | 34 |
| 63 | Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 67-74 | 7 | 33 |
| 62 | Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 253-62 | 7 | 32 |
| 61 | Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 273-9 | 6 | 31 |
| 60 | Impacto del tipo de hospital en el tratamiento y evoluci3n de los pacientes con s3ndrome coronario agudo sin elevaci3n del ST. <i>Revista Espanola De Cardiologia</i> , 2010 , 63, 390-399 | 1.5 | 29 |
| 59 | Lumen enlargement of the coronary segments located distal to chronic total occlusions successfully treated with drug-eluting stents at follow-up. <i>EuroIntervention</i> , 2014 , 9, 1181-8 | 3.1 | 27 |
| 58 | Pharmacodynamic effects of cangrelor on platelet P2Y ₁₂ receptor-mediated signaling in prasugrel-treated patients. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 426-34 | 5 | 25 |
| 57 | Platelet function and genetic testing. <i>Journal of the American College of Cardiology</i> , 2013 , 62, S21-31 | 15.1 | 23 |
| 56 | Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 1559-1571 | 5 | 22 |
| 55 | Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 35, 155-64 | 5.1 | 21 |
| 54 | Update on the clinical development of cangrelor. <i>Expert Review of Cardiovascular Therapy</i> , 2010 , 8, 1069-73 | 2.3 | 19 |
| 53 | Use of Impella Recover LP 2.5 in elective high risk percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2010 , 145, 235-237 | 3.2 | 19 |
| 52 | Mechanism of action and clinical development of platelet thrombin receptor antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2010 , 8, 1191-200 | 2.5 | 18 |
| 51 | Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 110-7 | 7 | 17 |
| 50 | Platelet adenosine diphosphate P2Y ₁₂ receptor antagonism: benefits and limitations of current treatment strategies and future directions. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010 , 63, 60-76 | 0.7 | 17 |
| 49 | Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation. <i>Journal of Cardiovascular Translational Research</i> , 2014 , 7, 39-46 | 3.3 | 16 |
| 48 | Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1681-7 | 15.1 | 16 |

| | | | |
|----|---|------|----|
| 47 | Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2011 , 4, 905-12 | 5 | 16 |
| 46 | Effects of pioglitazone on platelet P2Y ₁₂ -mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 930-6 | 7 | 13 |
| 45 | Preserved endothelial vasomotor function after everolimus-eluting stent implantation. <i>EuroIntervention</i> , 2015 , 11, 643-9 | 3.1 | 13 |
| 44 | Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019 , 71, 553-561 | 0.7 | 12 |
| 43 | Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 81, 42-9 | 2.7 | 12 |
| 42 | Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 1223-31 | 7 | 12 |
| 41 | Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020 , 73, 749-757 | 0.7 | 11 |
| 40 | Dual antiplatelet therapy after coronary stent implantation: Individualizing the optimal duration. <i>Journal of Cardiology</i> , 2018 , 72, 94-104 | 3 | 11 |
| 39 | Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 258-65 | 7 | 11 |
| 38 | Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 36, 14-7 | 5.1 | 11 |
| 37 | Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 361-9 | 2.5 | 11 |
| 36 | Multislice CT for assessing in-stent dimensions after left main coronary artery stenting: a comparison with three dimensional intravascular ultrasound. <i>Heart</i> , 2013 , 99, 1106-12 | 5.1 | 10 |
| 35 | Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5273-93 | 3.3 | 10 |
| 34 | Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTEMI-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. <i>European Heart Journal</i> , 2021 , 42, 2973-2985 | 9.5 | 10 |
| 33 | Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 182-4 | 5 | 8 |
| 32 | Impact of acute exacerbations on platelet reactivity in chronic obstructive pulmonary disease patients. <i>International Journal of COPD</i> , 2018 , 13, 141-148 | 3 | 8 |
| 31 | MGuard mesh-covered stent for treatment of ST-segment elevation myocardial infarction with high thrombus burden despite manual aspiration. <i>Journal of Interventional Cardiology</i> , 2013 , 26, 1-7 | 1.8 | 8 |
| 30 | Impact of gastric acid-suppressing therapies on platelet reactivity in patients with coronary artery disease treated with clopidogrel: results of a pharmacodynamic study. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 1396-8 | 15.1 | 8 |

| | | | |
|----|--|-----|---|
| 29 | High and low on-treatment platelet reactivity to P2Y inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2019 , 175, 95-101 | 8.2 | 7 |
| 28 | Predictive ability of bleeding risk scores in the routine clinical practice. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 205-10 | 4.3 | 7 |
| 27 | Coronary vasomotor function and myocardial flow with bioresorbable vascular scaffolds or everolimus-eluting metallic stents: a randomised trial. <i>EuroIntervention</i> , 2020 , 16, e155-e163 | 3.1 | 7 |
| 26 | Antithrombotic Therapy After Transcatheter Aortic Valve Implantation. <i>European Cardiology Review</i> , 2020 , 15, 1-8 | 3.9 | 6 |
| 25 | Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor. <i>Current Atherosclerosis Reports</i> , 2016 , 18, 66 | 6 | 6 |
| 24 | Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction: insights from the EXAMINATION trial. <i>American Heart Journal</i> , 2013 , 166, 119-26 | 4.9 | 5 |
| 23 | Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. <i>Diabetes and Vascular Disease Research</i> , 2010 , 7, 274-88 | 3.3 | 5 |
| 22 | One-year optical coherence tomography findings in patients with late and very-late stent thrombosis treated with intravascular imaging guided percutaneous coronary intervention. <i>International Journal of Cardiovascular Imaging</i> , 2018 , 34, 1511-1520 | 2.5 | 4 |
| 21 | Body mass index and acute coronary syndromes: paradox or confusion?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 158-64 | 4.3 | 3 |
| 20 | In Vivo Evaluation of the Synergic Effect of Metformin and mTOR Inhibitors on the Endothelial Healing of Drug-eluting Stents in Diabetic Patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018 , 71, 917-925 | 0.7 | 3 |
| 19 | IVUS Findings in Late and Very Late Stent Thrombosis. A Comparison Between Bare-metal and Drug-eluting Stents. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018 , 71, 335-343 | 0.7 | 3 |
| 18 | Impact of sex differences and network systems on the in-hospital mortality of patients with ST-segment elevation acute myocardial infarction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021 , 74, 927-934 | 0.7 | 3 |
| 17 | Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold. <i>Platelets</i> , 2016 , 27, 777-783 | 3.6 | 3 |
| 16 | Early anticoagulation may improve preprocedural patency of the infarct-related artery in primary percutaneous coronary intervention. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013 , 66, 148-50 | 0.7 | 2 |
| 15 | Oral antiplatelet therapy in patients with diabetes mellitus and acute coronary syndromes. <i>Trends in Cardiovascular Medicine</i> , 2010 , 20, 211-7 | 6.9 | 2 |
| 14 | Long-term prognostic impact of non-invasive follow-up with computed tomography angiography in patients with left main coronary artery stenting. <i>Minerva Cardioangiologica</i> , 2018 , 66, 528-535 | 1.1 | 2 |
| 13 | Comments on the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018 , 71, 6-12 | 0.7 | 1 |
| 12 | Ticagrelor in patients with myocardial infarction: is the treatment strategy crystal clear?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 207-209 | 6.4 | 1 |

| | | | |
|----|---|-----|---|
| 11 | Prediction of bleeding in patients with acute coronary syndromes: applying the new BARC definition. <i>Thrombosis Research</i> , 2014 , 133, 952-4 | 8.2 | 1 |
| 10 | Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012 , 65, 105-106 | 0.7 | 1 |
| 9 | Coronary endothelial and microvascular function distal to polymer-free and endothelial cell-capturing drug-eluting stents. The randomized FUNCOMBO trial. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021 , 74, 1013-1022 | 0.7 | 1 |
| 8 | Antithrombotic strategies in elderly patients with atrial fibrillation revascularized with drug-eluting stents: PACO-PCI (EPIC-15) registry. <i>International Journal of Cardiology</i> , 2021 , 338, 63-71 | 3.2 | 1 |
| 7 | Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes. <i>Journal of Clinical Medicine</i> , 2022 , 11, 3008 | 5.1 | 0 |
| 6 | Comentarios a la actualización ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria. <i>Revista Espanola De Cardiologia</i> , 2018 , 71, 6-12 | 1.5 | |
| 5 | Antithrombotic Therapy and Surgery: From Consensus to Clinical Practice. Response to Related Letters. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018 , 71, 879 | 0.7 | |
| 4 | Time since diabetes onset as a determining factor in platelet reactivity. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014 , 67, 243 | 0.7 | |
| 3 | Long-term Follow-up After Percutaneous Treatment of the Unprotected Left Main Stenosis in High Risk Patients Not Suitable for Bypass Surgery. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012 , 65, 530-537 | 0.7 | |
| 2 | Temporal trends in frequency, management and outcomes of coronary perforations. <i>Minerva Cardiology and Angiology</i> , 2018 , 66, 361-367 | 2.4 | |
| 1 | Association of fractalkine with functional severity of heart failure and impact on clopidogrel efficacy in patients with ischemic heart disease. <i>Thrombosis Research</i> , 2020 , 196, 215-221 | 8.2 | |